| Primary |
| Prophylaxis Against Transplant Rejection |
29.3% |
| Renal Transplant |
21.0% |
| Product Used For Unknown Indication |
15.1% |
| Prophylaxis |
13.4% |
| Transplant Rejection |
4.9% |
| Immunosuppression |
4.1% |
| Prophylaxis Against Graft Versus Host Disease |
2.1% |
| Type 1 Diabetes Mellitus |
2.0% |
| Kidney Transplant Rejection |
2.0% |
| Liver Transplant |
1.8% |
| Behcet's Syndrome |
0.8% |
| Antiviral Prophylaxis |
0.6% |
| Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis |
0.5% |
| Organ Transplant |
0.5% |
| Systemic Lupus Erythematosus |
0.4% |
| Infection |
0.3% |
| Infection Prophylaxis |
0.3% |
| Heart Transplant |
0.3% |
| Nephrotic Syndrome |
0.3% |
| Pancreas Transplant Rejection |
0.3% |
|
| Death |
42.8% |
| Transplant Rejection |
9.1% |
| Hospitalisation |
7.0% |
| Urinary Tract Infection |
5.3% |
| Anaemia |
3.3% |
| Cytomegalovirus Infection |
3.3% |
| Pulmonary Embolism |
2.9% |
| Kidney Transplant Rejection |
2.5% |
| Pneumonia |
2.5% |
| Respiratory Failure |
2.5% |
| Agranulocytosis |
2.1% |
| Blood Creatinine Increased |
2.1% |
| Cardiac Failure |
2.1% |
| Diabetes Mellitus |
2.1% |
| Infection |
2.1% |
| Pyelonephritis |
2.1% |
| Acute Myocardial Infarction |
1.6% |
| Aplasia Pure Red Cell |
1.6% |
| Febrile Neutropenia |
1.6% |
| Herpes Zoster |
1.6% |
|
| Secondary |
| Prophylaxis Against Transplant Rejection |
32.4% |
| Prophylaxis |
32.3% |
| Renal Transplant |
15.1% |
| Product Used For Unknown Indication |
4.2% |
| Type 1 Diabetes Mellitus |
3.2% |
| Kidney Transplant Rejection |
1.6% |
| Sedative Therapy |
1.4% |
| Heart Transplant |
1.0% |
| Liver Transplant |
1.0% |
| Hypertension |
0.9% |
| Prophylaxis Against Gastrointestinal Ulcer |
0.8% |
| Diarrhoea |
0.8% |
| Heart Transplant Rejection |
0.8% |
| Behcet's Syndrome |
0.8% |
| Cerebral Palsy |
0.7% |
| Thrombosis Prophylaxis |
0.7% |
| Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis |
0.6% |
| Transplant Rejection |
0.6% |
| Gastrointestinal Disorder |
0.5% |
| Lung Transplant |
0.5% |
|
| Upper Limb Fracture |
13.0% |
| Anaemia |
8.2% |
| White Blood Cell Count Decreased |
7.9% |
| Abdominal Pain |
6.5% |
| Cytomegalovirus Viraemia |
5.9% |
| Sinusitis |
5.9% |
| Herpes Zoster |
5.1% |
| Decreased Appetite |
4.5% |
| Uterine Leiomyoma |
4.2% |
| Hypertension |
4.0% |
| Neutropenia |
4.0% |
| Hepatic Neoplasm Malignant Recurrent |
3.7% |
| Pyrexia |
3.7% |
| Respiratory Failure |
3.7% |
| Agranulocytosis |
3.4% |
| Immunodeficiency Common Variable |
3.4% |
| Intra-abdominal Haemorrhage |
3.4% |
| Ovarian Cyst |
3.4% |
| Transplant Rejection |
3.1% |
| Cytomegalovirus Infection |
2.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
47.0% |
| Renal Transplant |
17.3% |
| Prophylaxis Against Transplant Rejection |
4.5% |
| Nuclear Magnetic Resonance Imaging |
4.3% |
| Liver Transplant |
3.8% |
| Heart Transplant |
2.8% |
| Hypertension |
2.7% |
| Diabetes Mellitus |
1.9% |
| Uveitis |
1.8% |
| Angiogram |
1.7% |
| Pain |
1.6% |
| Prophylaxis |
1.6% |
| Osteoporosis |
1.5% |
| Nuclear Magnetic Resonance Imaging Brain |
1.4% |
| Blood Pressure |
1.1% |
| Immunosuppression |
1.1% |
| Pulmonary Arterial Hypertension |
1.0% |
| Systemic Lupus Erythematosus |
1.0% |
| Vitamin Supplementation |
1.0% |
| Blood Cholesterol |
0.9% |
|
| Death |
17.3% |
| Renal Failure Acute |
10.0% |
| Fatigue |
6.7% |
| Anaemia |
5.3% |
| Drug Interaction |
4.7% |
| Pain |
4.7% |
| Renal Failure |
4.7% |
| Loss Of Consciousness |
4.0% |
| Nephrogenic Systemic Fibrosis |
4.0% |
| Pyrexia |
4.0% |
| Treatment Noncompliance |
4.0% |
| Vomiting |
4.0% |
| Abdominal Pain |
3.3% |
| Cholestasis |
3.3% |
| Drug Ineffective |
3.3% |
| Myocardial Infarction |
3.3% |
| Neuropathy Peripheral |
3.3% |
| Pneumonia |
3.3% |
| Systemic Lupus Erythematosus |
3.3% |
| Unevaluable Event |
3.3% |
|
| Interacting |
| Renal Transplant |
42.9% |
| Prophylaxis |
28.6% |
| Hypertension |
14.3% |
| Immunosuppression |
14.3% |
|
| Drug Interaction |
66.7% |
| Thrombotic Microangiopathy |
33.3% |
|
